Brigatinib FoundationOne companion diagnostic - Foundation Medicine/Takeda

Alternative Names: Brigatinib FoundationOne® CDx - Foundation Medicine/Takeda; Brigatinib FoundationOne®Liquid CDx

Latest Information Update: 15 Jul 2021

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

01 Jul 2021 Registered for Non-small cell lung cancer (Diagnosis) in USA
30 Jun 2021 Preregistration for Non-small cell lung cancer (Diagnosis) in USA before June 2021
21 Sep 2020 Foundation Medicine and Takeda Pharmaceuticals agree to develop brigatinib FoundationOne companion diagnostic for Non-small cell lung cancer

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com